The Safety and Efficacy of Roflumilast Foam in HS

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Beth Israel Deaconess Medical Center
Study ID
NCT07263230
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hidradenitis Suppurativa (HS)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study investigates the efficacy of topical roflumilast foam in patients with HS.

Key Dates

Start date
Apr 1, 2026
Status verified
Feb 2026
Primary completion
Mar 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Roflumilast 0.3% topical foam
    Roflumilast 0.3% topical foam to be applied QD to all active fields for the duration of the 16-week trial.

Primary Outcome Measure

Mean Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16. [ Time Frame: Baseline and Week 16 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Beth Israel Deaconess Medical CenterBostonMassachusetts02215
Martina Porter, MD
[email protected]
6176675834

Find similar trials in Boston, MA

By research site
Beth Israel Deaconess Medical Center· Boston, MA

Related Studies